Table 5_The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to trans

A pooled analysis of four randomized controlled trials (CARES-005, EMERALD-1, LEAP-012, TALENTACE) involving 1,431 patients with unresectable, non-metastatic hepatocellular carcinoma. Tonggang Zhou authored this analysis, which compares the combination of PD-1/PD-L1 inhibitors and anti-VEGF drugs with transarterial chemoembolisation alone. The data was last updated on 2026-05-25.

Use Cases

• Analyzing progression-free survival benefits based on hazard ratios and p-values reported in the pooled analysis
• Comparing objective response rates between treatment groups based on risk ratios
• Evaluating the incidence of grade 3-4 adverse events associated with combination therapy
• Assessing treatment discontinuation reasons based on patient status at data cutoff

Strengths

• Includes data from four randomized controlled trials, a rigorous study design
• Analyzes 1,431 patient records, providing a substantial sample size
• Reports specific hazard ratios (e.g., 0.62 for PFS) and risk ratios (e.g., 1.44 for ORR) with confidence intervals
• Examines outcomes using both RECIST 1.1 and mRECIST criteria

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is 111.0 KB, indicating a very limited scope likely containing summary statistics rather than raw patient-level data

Provenance

Source

figshare

Collection Method

Systematic search of six databases and pooled analysis of identified RCTs

Freshness

Last updated 2026-05-25 13:05:29; freshness should be verified